Research progress of non-alcoholic fatty liver disease after liver transplantation

doi:10.3877/cma.j.issn.1674-3903.2021.01.014

Abstract

Abstract:

Liver transplantation is an effective treatment for patients with various end-stage liver diseases, and the demand of graft livers is increasing. Non-alcoholic fatty liver disease (NAFLD) is getting more and more attention as a chronic liver disease. Recently, the international expert consensus has proposed a new name for NAFLD-metabolic associated fatty liver disease. With the increasing number of liver transplantation, the problems of NAFLD after transplantation have attracted more and more attention. This paper reviews the occurrence, risk factors, measures of prevention and treatment in NAFLD after liver transplantation.

Key words: Liver transplantation, Non-alcoholic fatty liver disease, Metabolic associated fatty liver disease, Risk factors, Prevention, Treatment

Zhiping Dang, Lina Ma, Wei Rao, Xinjuan Kong. Research progress of non-alcoholic fatty liver disease after liver transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(01): 60-63.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2021.01.014

https://zhyzzz.cma-cmc.com.cn/EN/Y2021/V15/I01/60

References 34

1	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Clin Liver Dis (Hoboken), 2018, 20, 11(4)：81.
2	Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1991.
3	Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1)：73-84.
4	Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.
5	Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis[J]. Hepatol Int, 2020，14(2)：259-269.
6	Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary[J]. J Gastroenterol Hepatol, 2007, 22(6): 775-777.
7	Kwon CHD, Joh JW, Lee KW, et al. Safety of donors with fatty liver in liver transplantation[J]. Transplant Proc, 2006, 38(7): 2106-2107.
8	Nikeghbalian S, Nejatollahi SMR, Salahi H, et al. Does donor′s fatty liver change impact on early mortality and outcome of liver transplantation[J]. Transplant Proc, 2007, 39(4): 1181-1183.
9	Trotter JF. Thin chance for fat people (to become living donors)[J]. Liver Transpl, 2001, 7(5): 415-417.
10	Brandhagen D, Fidler J, Rosen C. Evaluation of the donor liver for living donor liver transplantation[J]. Liver Transpl, 2003, 9(10 Suppl 2): S16-S28.
11	Kim H, Lee K, Lee KW, et al. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation[J]. Clin Transplant, 2014, 28(5): 521-529.
12	Kim H, Lee KW, Lee K, et al. Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients[J]. Hepatol Res, 2018, 48(3): E162-E171.
13	Narayanan P, Mara K, Izzy M, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation[J]. Transplantation, 2019, 103(1): e14-e21.
14	Vallin M, Guillaud O, Boillot O, et al. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis[J]. Liver Transpl, 2014, 20(9)：1064-1071.
15	Germani G, Laryea M, Rubbia-Brandt L, et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation[J]. Transplantation, 2019, 103(1): 57-67.
16	Narayanan P, Mara K, Dierkhising R, et al. 425 underlying NASH and recurrent or de novo allograft steatosis are predictive of long term cardiovascular events in liver transplant recipients[J]. Gastroenterology, 2016, 150(4): S1033.
17	Hanouneh IA, Macaron C, Lopez R, et al. Recurrence of disease following liver transplantation: nonalcoholic steatohepatitis vs hepatitis C virus infection[J]. Int J Organ Transplant Med, 2011, 2(2): 57-65.
18	Alten TA, Negm AA, Voigtländer T, et al. Safety and performance of liver biopsies in liver transplant recipients[J]. Clin Transplant, 2014, 28(5): 585-589.
19	van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved ¹H MR spectroscopy[J]. Radiology, 2010, 256(1): 159-168.
20	Hepburn MJ, Vos JA, Fillman EP, et al. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study[J]. BMC gastroenterology, 2005, 5: 14.
21	Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis[J]. PLoS One, 2017, 12(9): e0185192.
22	Pfitzmann R, Nüssler NC, Hippler-Benscheidt M, et al. Long-term results after liver transplantation[J]. Transpl Int, 2008, 21(3): 234-246.
23	Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events[J]. Liver Transpl, 2007, 13(8): 1109-1114.
24	Bianchi G, Marchesini G, Marzocchi R, et al. Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression[J]. Liver Transpl, 2008, 14(11)：1648-1654.
25	Miller LW. Cardiovascular toxicities of immunosuppressive agents[J]. Am J Transplant, 2002, 2(9): 807-818.
26	Charlton M, Rinella M, Patel D, et al. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: Results of a randomized multicenter study[J]. Transplantation, 2017, 101(12): 2873-2882.
27	Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of " seed and soil" [J]. Am J Gastroenterol, 2010, 105(3): 613-620.
28	Hübscher SG. What is the long-term outcome of the liver allograft？[J]. J Hepatol, 2011, 55(3): 702-717.
29	Finkenstedt A, Auer C, Glodny B, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis[J]. Clin Gastroenterol Hepatol, 2013, 11(12): 1667-1672.
30	Miyaaki H, Miuma S, Taura N, et al. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C[J]. Hepatol Res, 2018, 48(3): E335-E339.
31	Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2014, 46(4): 352-356.
32	Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis[J]. Hepatology, 2015, 62(6): 1742-1756.
33	Textor SC, Taler SJ, Canzanello VJ, et al. Posttransplantation hypertension related to calcineurin inhibitors[J]. Liver Transpl, 2000, 6(5)：521-530.
34	Mohameda O, Jamesp W. FDA adverse event reports on statin-associated rhabdomyolysis[J]. Ann Pharmacother, 2002, 36(2): 288-295.

[1]	Huanyan Liu, Yang Hua, Lingyun Jia, Xinyu Zhao, Beibei Liu. Lumen structure and hemodynamic characteristics of occluded internal carotid artery [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 809-815.
[2]	Yanbo Ma, Yang Hua, Guimei Liu, Xiufeng Meng, Liping Cui. Risk factors for carotid atherosclerotic lesions in middle adults [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 822-826.
[3]	Hongyu Wang. Application value of fixed and mobile platform prostheses in total knee arthroplasty [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 871-876.
[4]	Yingxiong Huang, Zi Ye, Peng Jiang, Hong Zhan, Chen Yao, Ji Cui. Clinical risk factors for transmural intestinal necrosis in acute mesenteric venous thrombosis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 413-421.
[5]	Zaibo Zhang, Bingyu Wang, Zhikai Jiao, Bibo Tan. Risk factors for lower extremity deep venous thrombosis after gastric cancer surgery: A Meta-analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 475-480.
[6]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[7]	Fangyuan Wu, Xia Sun, Changfeng Lin, Zhensheng Zhang. Risk factors of HBV-associated cirrhosis complicated with acute upper gastrointestinal bleeding [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 45-47.
[8]	Xu Peng, Yongfu Shao, Duo Li, Rui Zhou, Zhenming Xing. Diagnosis and surgical treatment of hepatocolon flexure [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 108-110.
[9]	Weiqiang Ma, Binlin Ma, Zhongyu Wu, Ying Zhang. The role of microRNA in the progression of triple-negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 111-114.
[10]	Yonghuan Mao, Hanwen Tong, Ji Miao, Xingzhou Wang, Xiaofei Shen, Chunzhao Yu. Analysis of risk factors and prediction model of parastomal hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 682-687.
[11]	Ming Jiang, Rui Luo, Chengchao Long. Diagnosis and treatment of obturator hernia: An experience of 73 cases over 10 years [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 706-710.
[12]	Menggui Lu, Bin Huang, Qiulin Li, Yuanmei He. Risk factors for multiple organ dysfunction syndrome in patients with bee sting injury [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 1010-1015.
[13]	Da Li, Daya Zhang, Runxiang Chen, Xiaodong Zhang, Shimei Huang, Chen Chen, fan Zeng, Shiju Chen, Feihu Bai. Epidemiological characteristics and risk factors of Helicobacter pylori infection in Dongfang city of Hainan province [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 858-864.
[14]	Zhifeng Lu, Jiajia Zhou, Shu Liang. Advances in application and research of virtual reality technology in amblyopia treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 891-895.
[15]	Tian Li, Hong Xu, Heliang Liu. Progress in research of pneumoconiosis [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 900-905.

Please choose a citation manager

Content to export